# Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone

> **NCT00931125** · PHASE2 · UNKNOWN · sponsor: **Attila Vajas** · enrollment: 70 (estimated)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** ranibizumab and vitrectomy
- **PROCEDURE:** vitrectomy without preoperative ranibizumab

## Key facts

- **NCT ID:** NCT00931125
- **Lead sponsor:** Attila Vajas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-03
- **Primary completion:** 2013-09
- **Final completion:** 2013-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2013-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00931125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00931125, "Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00931125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*